Ex-Div Reminder For West Bancorporation (WTBA)

Looking at the universe of stocks we cover at Dividend Channel, on 11/4/13, West Bancorporation, Inc. (WTBA) will trade ex-dividend, for its quarterly dividend of $0.11, payable on 11/26/13. As a percentage of WTBA's recent stock price of $14.16, this dividend works out to approximately 0.78%, so look for shares of West Bancorporation, Inc. to trade 0.78% lower — all else being equal — when WTBA shares open for trading on 11/4/13.

START SLIDESHOW:
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »

Below is a dividend history chart for WTBA, showing historical dividends prior to the most recent $0.11 declared by West Bancorporation, Inc.:

WTBA+Dividend+History+Chart

In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from WTBA is likely to continue, and whether the current estimated yield of 3.11% on annualized basis is a reasonable expectation of annual yield going forward.The chart below shows the one year performance of WTBA shares, versus its 200 day moving average:

West Bancorporation, Inc. 200 Day Moving Average Chart

Looking at the chart above, WTBA's low point in its 52 week range is $9.75 per share, with $14.50 as the 52 week high point — that compares with a last trade of $14.17.

In Thursday trading, West Bancorporation, Inc. shares are currently up about 0.4% on the day.

null

More from Stocks

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says